These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32665438)

  • 1. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo.
    Wang P; Gajjar MR; Yu J; Padte NN; Gettie A; Blanchard JL; Russell-Lodrigue K; Liao LE; Perelson AS; Huang Y; Ho DD
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18002-18009. PubMed ID: 32665438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.
    Asokan M; Dias J; Liu C; Maximova A; Ernste K; Pegu A; McKee K; Shi W; Chen X; Almasri C; Promsote W; Ambrozak DR; Gama L; Hu J; Douek DC; Todd JP; Lifson JD; Fourati S; Sekaly RP; Crowley AR; Ackerman ME; Ko SH; Kilam D; Boritz EA; Liao LE; Best K; Perelson AS; Mascola JR; Koup RA
    Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18754-18763. PubMed ID: 32690707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
    Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
    J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
    Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
    EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-retroviral antibody FcγR-mediated effector functions.
    Bournazos S; Ravetch JV
    Immunol Rev; 2017 Jan; 275(1):285-295. PubMed ID: 28133801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
    von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
    J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
    Parsons MS; Chung AW; Kent SJ
    Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
    Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
    Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
    Moldt B; Schultz N; Dunlop DC; Alpert MD; Harvey JD; Evans DT; Poignard P; Hessell AJ; Burton DR
    J Virol; 2011 Oct; 85(20):10572-81. PubMed ID: 21849450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
    Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
    J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
    Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L
    PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features.
    Cheng HD; Dowell KG; Bailey-Kellogg C; Goods BA; Love JC; Ferrari G; Alter G; Gach J; Forthal DN; Lewis GK; Greene K; Gao H; Montefiori DC; Ackerman ME
    Retrovirology; 2021 Oct; 18(1):35. PubMed ID: 34717659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.
    Bournazos S; Klein F; Pietzsch J; Seaman MS; Nussenzweig MC; Ravetch JV
    Cell; 2014 Sep; 158(6):1243-1253. PubMed ID: 25215485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc receptor-mediated antiviral antibodies.
    Forthal DN; Moog C
    Curr Opin HIV AIDS; 2009 Sep; 4(5):388-93. PubMed ID: 20048702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
    Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
    Front Immunol; 2022; 13():893648. PubMed ID: 35651621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity.
    Goldberg BS; Kaku CI; Dufloo J; Bruel T; Schwartz O; Spencer DA; Hessell AJ; Ackerman ME
    mBio; 2021 Oct; 12(5):e0174321. PubMed ID: 34634936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
    Front Immunol; 2018; 9():244. PubMed ID: 29651286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.